Cagrilintide Dosage Chart: How Dosing Works

What Cagrilintide Is and Why Dosing Matters

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk and administered as a once-weekly subcutaneous injection. Unlike GLP-1 receptor agonists, which primarily slow gastric emptying and stimulate insulin release, cagrilintide mimics the hormone amylin to slow digestion, reduce appetite, and lower glucagon secretion. The combined effect makes it a promising tool for obesity management, both on its own and in combination with other agents.

Why does the dosing schedule matter so much? Because jumping to a high dose immediately would likely cause significant nausea, vomiting, or other gastrointestinal reactions. Gradual dose escalation gives the digestive system time to adapt, improves long-term tolerability, and helps more patients stay on therapy long enough to see meaningful results. Understanding this titration logic is just as important as knowing the specific milligram amounts at each stage.

Cagrilintide is also being studied alongside semaglutide in a co-formulated product called CagriSema, which adds another layer of dosing complexity worth understanding separately.

The Step-by-Step Titration Schedule

In clinical trials, cagrilintide escalation follows a consistent pattern. Doses increase in increments every four weeks, with the weekly injection frequency staying constant throughout. Only the amount of medication changes at each step.

The escalation moves through five stages: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. At that final level, the patient has reached the maintenance dose, meaning the therapeutic target observed in Phase 3 trials. Most participants hit this milestone somewhere between weeks 16 and 20, depending on how smoothly their titration progresses.

If gastrointestinal side effects become difficult to manage at any point, clinical guidance allows for the titration to be paused or slowed. This flexibility is intentional. The schedule is a framework, not a rigid requirement, and individual responses to each dose step can vary considerably.

Cagrilintide Dosage Chart: Step-by-Step Reference

The table below summarizes the escalation steps used in cagrilintide clinical trials. Dosing intervals remain weekly at every stage; only the milligram amount increases.

This titration logic mirrors what has been used for semaglutide and tirzepatide, reflecting a broader industry approach to managing tolerability in obesity medications. The 2.4 mg maintenance dose is not a ceiling chosen arbitrarily. It is the level at which Phase 3 trial data showed clinically meaningful weight reduction while remaining tolerable for most participants.

One important distinction: the word "maintenance" here is a clinical term meaning the intended long-term therapeutic dose, not a dose that can be self-adjusted based on personal preference or perceived progress.

CagriSema Combination Dosing: What Changes

CagriSema pairs cagrilintide 2.4 mg with semaglutide 2.4 mg in a single co-formulated injection given once weekly. Because both active ingredients are present simultaneously, the titration schedule escalates both components in parallel rather than one at a time.

This distinction matters. Patients familiar with standalone semaglutide titration, or who have reviewed cagrilintide dose charts, should not assume those schedules apply directly to CagriSema. The combination product has its own approved escalation framework from Novo Nordisk's REDEFINE Phase 3 trial program.

Phase 3 REDEFINE data suggested that CagriSema produced greater average weight loss than either cagrilintide or semaglutide alone. That finding has generated significant interest, but it also underscores the importance of using the correct dosage chart for the correct product. Confusing the two could mean either under-dosing or exposing yourself to a faster escalation than your body is ready to handle.

Factors That May Influence Your Personal Dosing Pace

Several individual factors can affect how quickly or slowly someone moves through the titration schedule.

Kidney or liver impairment may reduce how well the body processes and tolerates increasing doses, potentially requiring a more cautious approach. Gastrointestinal side effects, particularly nausea and vomiting, are the most common reasons a clinician might pause titration at a given step. Prior experience with GLP-1 receptor agonists may mean a somewhat smoother adjustment for some patients, though this is not guaranteed.

Body weight, the presence of conditions like type 2 diabetes, and overall metabolic health all factor into how a clinician sets the pace of escalation. Because cagrilintide is not yet FDA approved, all of these decisions currently happen within clinical trial protocols or investigational frameworks rather than standard prescribing practice.

Doctronic, the first AI legally authorized to practice medicine in the United States, offers 24/7 consultations for patients trying to navigate complex questions about emerging obesity therapies like this one.

What to Know Before Starting or Researching This Therapy

Cagrilintide is self-administered using a pre-filled pen injector, similar in delivery to the devices used for semaglutide. Proper injection technique, site rotation, and storage conditions are all part of safe use, and these details should be reviewed with a healthcare provider or trial coordinator before beginning.

If a weekly dose is missed, the right course of action depends on timing. General guidance typically advises against doubling up, but the specific window for catching up versus skipping varies. Getting clear instructions from a clinician rather than improvising is the safest approach.

Perhaps most importantly, any dosage chart found online, including this one, reflects clinical trial data and general protocol frameworks. Individual prescribing decisions, especially for an investigational drug, can differ from published schedules based on a patient's unique health profile. A free AI consultation through Doctronic can help you understand where this therapy stands today and whether trial eligibility or future prescription access might apply to your situation.

The Bottom Line

Cagrilintide follows a carefully structured dose escalation, starting at 0.25 mg weekly and building to a 2.4 mg maintenance dose over roughly 16 to 20 weeks. This approach is designed to help the body adapt and reduce gastrointestinal discomfort along the way. The combination product CagriSema uses its own parallel titration chart, and both protocols remain investigational as of early 2025 with no current FDA approval. Doctronic, which has conducted more than 22 million AI consultations with 99.2% treatment plan alignment with board-certified physicians, can help you understand where cagrilintide stands and whether emerging obesity therapies may be relevant to your situation. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.